Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | ACVR2A | P27037 | 4/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 4/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94423 | 0.83 | CCR1 (0.55) | MAPTDYRK1ACYP19A1WNT3AACVR2A | |
| SCHEMBL18034739 | 0.81 | MAPT (0.46) | MAPTDYRK1ACYP19A1WNT3AACVR2A | |
| SCHEMBL19762807 | 0.78 | IDO1 (0.54) | CYP19A1LOXLOXL2TGFBR1GRIA2 | |
| SCHEMBL132252 | 0.77 | GABRA1 (0.46) | MAPTDYRK1ACYP19A1WNT3AACVR2A | |
| SCHEMBL30626327 | 0.76 | LOX (0.55) | CNR1MAPTDYRK1ACYP19A1ACVR2A | |
| SCHEMBL16116782 | 0.76 | LOX (0.55) | CNR1MAPTDYRK1ACYP19A1ACVR2A | |
| SCHEMBL27111217 | 0.75 | MAPT (0.47) | CNR1MAPTDYRK1ACYP19A1ACVR2A | |
| SCHEMBL29890121 | 0.73 | LRRK2 (0.48) | CNR1DYRK1ACYP19A1ACVR2ATGFBR2 | |
| SCHEMBL16385279 | 0.73 | KDM4E (0.48) | MAPT | |
| SCHEMBL30078861 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618299-B2 | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| WO-2011003012-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | CNR1 44/4885MAPT 4227/4885DYRK1A 2587/4885 |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | CNR1 44/4885MAPT 4227/4885DYRK1A 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.